✦ LIBER ✦

Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study

✍ Scribed by Iwata, Hiroji; Fujii, Hirofumi; Masuda, Norikazu; Mukai, Hirofumi; Nishimura, Yuichiro; Katsura, Koichi; Ellis, Catherine E.; Gagnon, Robert C.; Nakamura, Seigo

Book ID: 120959165
Publisher: Springer Japan
Year: 2013
Tongue: English
Weight: 300 KB
Volume: 22
Category: Article
ISSN: 1340-6868
DOI: 10.1007/s12282-013-0475-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Lapatinib monotherapy in patients with r

Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies

✍ Toi, M; Iwata, H; Fujiwara, Y; Ito, Y; Nakamura, S; Tokuda, Y; Taguchi, T; Rai, 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 386 KB

Clinical outcomes of HER2-positive metas

Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea

✍ Jungsil Ro, Sohee Park, Sung- Bae Kim, Tae You Kim, Young Hyuk Im, Sun Young Rha 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 287 KB

A Phase I Study of an All-Oral Combinati

A Phase I Study of an All-Oral Combination of Vinorelbine/Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines and/or Taxanes

✍ Pirkko-Liisa Kellokumpu-Lehtinen; Kaisa Sunela; Ilari Lehtinen; Heikki Joensuu; 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 125 KB

Efficacy and safety of ixabepilone in ta

Efficacy and safety of ixabepilone in taxane-resistant patients with metastatic breast cancer previously treated with anthracyclines: results of a phase II study in Japan

✍ Kenjiro Aogi, Yoshiaki Rai, Yoshinori Ito… 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 216 KB

Overall Survival Benefit With Lapatinib

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

✍ Blackwell, K. L.; Burstein, H. J.; Storniolo, A. M.; Rugo, H. S.; Sledge, G.; Ak 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 203 KB

Results of a phase II study of liposomal

Results of a phase II study of liposomal doxorubicin (Myocet®) in combination with weekly paclitaxel and trastuzumab (Herceptin®) In patients with HER2-positive locally advanced or metastatic breast cancer (LA/MBC)

✍ J Baselga; M.A Climent; A Lluch; J Hornedo; P Gascon; A.T Sanchez; V Guillem; H 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 173 KB